Harmony Biosciences Holdings (HRMY) Operating Margin (2020 - 2026)
Harmony Biosciences Holdings recorded quarterly Operating Margin of 3.87% in Q1 2026, up 107.56% quarter-over-quarter from 51.17% in Q4 2025, and down 2658.0% year-over-year from 0.15% in Q1 2025.
Harmony Biosciences Holdings' Operating Margin history runs 7 years deep, the most recent figure standing at 3.87% for Q1 2026.
- In Q1 2026, Operating Margin fell 2658.0% year-over-year to 3.87%; the TTM figure through Mar 2026 stood at 0.31% (down 2649.0% YoY), while the FY2025 annual figure was 5.2%, down 2150.0% from the prior year.
- Operating Margin came in at 3.87% for Q1 2026 at Harmony Biosciences Holdings, up from 51.17% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 40.25% in Q3 2023 to a low of 51.17% in Q4 2025.
- A 5-year average of 22.64% and a median of 30.45% in 2025 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin jumped 3010 bps in 2023 and plunged 7886 bps in 2025, its largest moves.
- Harmony Biosciences Holdings' Operating Margin stood at 37.11% in 2022, then plunged by 36 bps to 23.87% in 2023, then climbed by 16 bps to 27.69% in 2024, then sank by 285 bps to 51.17% in 2025, then jumped by 108 bps to 3.87% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 3.87%, 51.17%, and 27.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | 3.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.87% |
| Dec 31, 2025 | -51.17% |
| Sep 30, 2025 | 27.35% |
| Jun 30, 2025 | 24.03% |
| Mar 31, 2025 | 30.45% |
| Dec 31, 2024 | 27.69% |
| Sep 30, 2024 | 33.17% |
| Jun 30, 2024 | 12.36% |
| Mar 31, 2024 | 33.65% |
| Dec 31, 2023 | 23.87% |
| Sep 30, 2023 | 40.25% |
| Jun 30, 2023 | 34.95% |
| Mar 31, 2023 | 33.93% |
| Dec 31, 2022 | 37.11% |
| Sep 30, 2022 | 10.15% |
| Jun 30, 2022 | 30.94% |
| Mar 31, 2022 | 32.30% |
| Dec 31, 2021 | 31.39% |
| Sep 30, 2021 | 26.08% |
| Jun 30, 2021 | 31.58% |
| Mar 31, 2021 | 24.35% |
| Dec 31, 2020 | 13.78% |
| Sep 30, 2020 | 22.76% |
| Jun 30, 2020 | 19.23% |
| Mar 31, 2020 | -48.43% |